AAAAAA

   
Results: 1-12 |
Results: 12
TREATING DEPRESSION IN MANAGED CARE ORGANIZATIONS - WHAT DO PRIMARY-CARE PROVIDERS THINK, KNOW, AND DO ABOUT IT
Authors: MEREDITH LS WELLS KB ROST K NUTTING P FORD DE GORDON N RUBINSTEIN LV
Citation: Ls. Meredith et al., TREATING DEPRESSION IN MANAGED CARE ORGANIZATIONS - WHAT DO PRIMARY-CARE PROVIDERS THINK, KNOW, AND DO ABOUT IT, International journal of psychiatry in medicine, 27(4), 1997, pp. 313-314
AN INFORMATION-INTENSIVE APPROACH TO THE MOLECULAR PHARMACOLOGY OF CANCER
Authors: WEINSTEIN JN MYERS TG OCONNOR PM FRIEND SH FORNACE AJ KOHN KW FOJO T BATES SE RUBINSTEIN LV ANDERSON NL BUOLAMWINI JK VANOSDOL WW MONKS AP SCUDIERO DA SAUSVILLE EA ZAHAREVITZ DW BUNOW B VISWANADHAN VN JOHNSON GS WITTES RE PAULL KD
Citation: Jn. Weinstein et al., AN INFORMATION-INTENSIVE APPROACH TO THE MOLECULAR PHARMACOLOGY OF CANCER, Science, 275(5298), 1997, pp. 343-349
VAGINAL CLEAR-CELL ADENOCARCINOMA IN THE UNITED-STATES
Authors: TRIMBLE EL RUBINSTEIN LV MENCK HR HANKEY BF KOSARY C GIUSTI RM
Citation: El. Trimble et al., VAGINAL CLEAR-CELL ADENOCARCINOMA IN THE UNITED-STATES, Gynecologic oncology, 61(1), 1996, pp. 113-115
ENHANCED SENSITIVITY TO 1-BETA-D-ARABINOFURANOSYLCYTOSINE AND TOPOISOMERASE-II INHIBITORS IN TUMOR-CELL LINES HARBORING ACTIVATED RAS ONCOGENES
Authors: KOO HM MONKS A MIKHEEV A RUBINSTEIN LV GRAYGOODRICH M MCWILLIAMS MJ ALVORD WG OIE HK GAZDAR AF PAULL KD ZARBL H VANDEWOUDE GF
Citation: Hm. Koo et al., ENHANCED SENSITIVITY TO 1-BETA-D-ARABINOFURANOSYLCYTOSINE AND TOPOISOMERASE-II INHIBITORS IN TUMOR-CELL LINES HARBORING ACTIVATED RAS ONCOGENES, Cancer research, 56(22), 1996, pp. 5211-5216
LOBECTOMY VERSUS LIMITED RESECTION IN T1 N0 LUNG-CANCER - REPLY
Authors: RUBINSTEIN LV GINSBERG RJ
Citation: Lv. Rubinstein et Rj. Ginsberg, LOBECTOMY VERSUS LIMITED RESECTION IN T1 N0 LUNG-CANCER - REPLY, The Annals of thoracic surgery, 62(4), 1996, pp. 1249-1250
ENHANCED SENSITIVITY TO CYTOSINE-ARABINOSIDE AND TOPOISOMERASE-II INHIBITORS IN TUMOR-CELL LINES HARBORING MUTATIONS IN RAS ONCOGENES
Authors: KOO HM MONKS A MIKHEEV A RUBINSTEIN LV GRAYGOODRICH M MCWILLIAMS MJ OIE HK GAZDAR AF PAULL KD ZARBL H VANDEWOUDE GF
Citation: Hm. Koo et al., ENHANCED SENSITIVITY TO CYTOSINE-ARABINOSIDE AND TOPOISOMERASE-II INHIBITORS IN TUMOR-CELL LINES HARBORING MUTATIONS IN RAS ONCOGENES, Blood, 86(10), 1995, pp. 2037-2037
RANDOMIZED TRIAL OF LOBECTOMY VERSUS LIMITED RESECTION FOR T1 N0 NON-SMALL-CELL LUNG-CANCER
Authors: HOLMES CE RUCKDESCHEL JC JOHNSTON M THOMAS PA DESLAURIERS J GROVER FL HILL LD FELD R GINSBERG RJ MOUNTAIN CF DZUIBAN S KIELY M MCKNEALLY MF MOORES DWO RAMNES C WAGNER H BUNN P CHU H DIENHART D HAZUKA M KINZIE J SORENSEN J VANCE V BRAUN T HOPEMAN A KANE M RUSS P WHITMAN GJR FALL SM HANSEN DP HENDERSON RH MONCRIEF CL PAULING F SIMS J TELL D WISELYCARR S ABERNATHY CM CLARK DA MCCROSKEY B MOORE G MOORE F MYERS A WHITE M BROOKS RJ BULL M JOHNSON FB NEIMYR M PAQUETTE FR SACCOMANNO G LAD T HERMANSEN K LIEBNER E MCGUIRE WP FRY W STEMPELFELD B ALEXANDER JC BECK J GARCES RM IMPERATO JP KAHANDEKAR J KNOP R LOCKER G MERKEL DE PANELLA JS ROCHESTER D VICTOR TA JOHNSON C JOOB AW ROBINSON P ROSEN S SHIELDS T DOOLEY S TIO FO HOLLAND C TREASURE RL GOTTFRIED B BEDDINGFIELD G BOWER J CHENG D DALY MB LADD WA LEACH C MURPHY K QUINTON R SMITH VC YOUNG ME BLANTON M BRIGGS R GRISHKIN BA HELSEL R JACKSON D JACKSON ME YOUNG R ZALOZNIK A BLOCK K DAIL DH DREIS D GUYTON SW HAFERMANN M HAMMAR SP JOLLY PC MORGAN E SPRINGMEYER S TAYLOR EW WEIDEN PW KNUDSEN N LIVINGSTON RB RUSCH VW GRAFTON C LERICHE J MURRAY N PAGE R GOODMAN GE AYE RW EVANS KG MILLER RR NELEMS B HIGANO C BERGSAGEL D BROWN TC CURTIS J PAYNE D PRINGLE JF QUIRT I STEWARD L WARR D YEOH L BURKES R COOTER N GOLDBERG M MULLEN B SCHMOCKER B HARRIS F ILVES R SINCLAIR JM SPRATT E BAKER M CHAMBERLAIN DW COOPER JD DESANTIS D EVANS WK PATTERSON GA PEARSON FG RITCHIE AC SHEPHERD FA TAYLOR D TODD TRJ WEBSTER J WINTON TL KIRBY TJ LIPA M FRENCH S SUTTON D WARNER E WATERS PF JONES D HOLMES EC SELCH RA SHIPLACOFF J GANZ P SILVERMAN B HASKELL C SADEGHI A WILLIAMS A WOLLMAN J BLOCH JH CORDER MP HERMES K LUKEMAN JM MURPHY A PIANTADOSI S GOODMAN S RUBINSTEIN LV GAIL MH BOSSENGA M LAKE WH LONG S
Citation: Ce. Holmes et al., RANDOMIZED TRIAL OF LOBECTOMY VERSUS LIMITED RESECTION FOR T1 N0 NON-SMALL-CELL LUNG-CANCER, The Annals of thoracic surgery, 60(3), 1995, pp. 615-622
PREDICTIVE STATISTICS AND ARTIFICIAL-INTELLIGENCE IN THE TITUTES-DRUG-DISCOVERY-PROGRAM-FOR-CANCER-AND-AIDS
Authors: WEINSTEIN JN MYERS T BUOLAMWINI J RAGHAVAN K VANOSDOL W LICHT J VISWANADHAN VN KOHN KW RUBINSTEIN LV KOUTSOUKOS AD MONKS A SCUDIERO DA ANDERSON NL ZAHAREVITZ D CHABNER BA GREVER MR PAULL KD
Citation: Jn. Weinstein et al., PREDICTIVE STATISTICS AND ARTIFICIAL-INTELLIGENCE IN THE TITUTES-DRUG-DISCOVERY-PROGRAM-FOR-CANCER-AND-AIDS, Stem cells, 12(1), 1994, pp. 13-22
DISCRIMINATION TECHNIQUES APPLIED TO THE NCI IN-VITRO ANTITUMOR DRUG SCREEN - PREDICTING BIOCHEMICAL-MECHANISM OF ACTION
Authors: KOUTSOUKOS AD RUBINSTEIN LV FARAGGI D SIMON RM KALYANDRUG S WEINSTEIN JN KOHN KW PAULL KD
Citation: Ad. Koutsoukos et al., DISCRIMINATION TECHNIQUES APPLIED TO THE NCI IN-VITRO ANTITUMOR DRUG SCREEN - PREDICTING BIOCHEMICAL-MECHANISM OF ACTION, Statistics in medicine, 13(5-7), 1994, pp. 719-730
A COMPARISON OF 2 PHASE-I TRIAL DESIGNS
Authors: KORN EL MIDTHUNE D CHEN TT RUBINSTEIN LV CHRISTIAN MC SIMON RM
Citation: El. Korn et al., A COMPARISON OF 2 PHASE-I TRIAL DESIGNS, Statistics in medicine, 13(18), 1994, pp. 1799-1806
PRECLINICAL ANTITUMOR-ACTIVITY OF TEMOZOLOMIDE IN MICE - EFFICACY AGAINST HUMAN BRAIN-TUMOR XENOGRAFTS AND SYNERGISM WITH 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA
Authors: PLOWMAN J WAUD WR KOUTSOUKOS AD RUBINSTEIN LV MOORE TD GREVER MR
Citation: J. Plowman et al., PRECLINICAL ANTITUMOR-ACTIVITY OF TEMOZOLOMIDE IN MICE - EFFICACY AGAINST HUMAN BRAIN-TUMOR XENOGRAFTS AND SYNERGISM WITH 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA, Cancer research, 54(14), 1994, pp. 3793-3799
RANDOMIZED PHASE-III TRIAL OF TREATMENT WITH HIGH-DOSE INTERLEUKIN-2 EITHER ALONE OR IN COMBINATION WITH INTERFERON ALFA-2A IN PATIENTS WITH ADVANCED MELANOMA
Authors: SPARANO JA FISHER RI SUNDERLAND M MARGOLIN K ERNEST ML SZNOL M ATKINS MB DUTCHER JP MICETICH KC WEISS GR DOROSHOW JH ARONSON FR RUBINSTEIN LV MIER JW
Citation: Ja. Sparano et al., RANDOMIZED PHASE-III TRIAL OF TREATMENT WITH HIGH-DOSE INTERLEUKIN-2 EITHER ALONE OR IN COMBINATION WITH INTERFERON ALFA-2A IN PATIENTS WITH ADVANCED MELANOMA, Journal of clinical oncology, 11(10), 1993, pp. 1969-1977
Risultati: 1-12 |